BioMedNewsBreaks

ThursdayFeb 11, 2021 10:16 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Ability to Speed Up COVID-19 Testing Using PCR Equipment

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has partnered with a German diagnostics firm to become a leader in commercializing breakthrough tech in rapid, definitive testing for COVID-19 in strategic and convenient point-of-care (“POC”) settings. A recent article noted that, using standard polymerase chain reaction (“PCR”) equipment, XPhyto has the ability to significantly speed up testing for COVID-19. The equipment is commonly found in most analytical laboratories as well as hospitals and a range of POC settings. The announcement was based on the successful trial validation results of XPhyto’s…

Continue Reading

ThursdayFeb 11, 2021 10:12 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.4M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock. The company expects gross proceeds of approximately $7.4 million, with each of the shares sold a purchase price of $1.75, in the registered direct offering priced at-the-market under Nasdaq rules. Predictive Oncology has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of approximately 2,111,114 shares…

Continue Reading

WednesdayFeb 10, 2021 3:14 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Provides Antigen Rapid POC Test as part of Comprehensive COVID-19 Strategy

United Medical Equipment (“UME,” “UMEBSNI”) is committed to offering high-quality COVID-19 services, solutions and supplies. Among these, UME provides the CareStart(TM) COVID-19 Antigen Rapid POC test. The test can be administered by authorized laboratories and at the point of care by medical professionals to detect the presence of the SARS-CoV-2 nucleocapsid protein antigen. The innovative test features a 10-minute processing time and provides the capability to identify acute infection with 88.4% sensitivity and 100% specificity. A recent article discussing this reads, “The CareStart product is part of a UME’s comprehensive COVID-19 monitoring strategy, which was carefully designed with the assistance…

Continue Reading

WednesdayFeb 10, 2021 3:03 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Anticipates ‘Breakout Year’ in 2021

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, expects to achieve important milestones in the year ahead. The company’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’ ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. The system’s key feature is its adaptability to almost any scope already in use by hospitals and surgical centers. Despite the challenges of 2020, Imagin was able to transition its product from the development stage to manufacturing, contracting with FDA registered and ISO 13485:2016-certified manufacturer Lighthouse Imaging.…

Continue Reading

WednesdayFeb 10, 2021 12:38 pm

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Configures MiQLab(TM) to Detect Variants of COVID-19 Pathogen

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has successfully configured a MiQLab(TM) system to detect mutant sequences unique to the United Kingdom (“UK, B.1.1.7”) 1 and South African (“SA, B.1.351”) 2 variants of SARS-CoV-2, the pathogen that causes COVID-19.  “Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab,” said Dr. Jack Regan, LexaGene’s CEO and founder. “After just two full work days of having these reagents in-house,…

Continue Reading

WednesdayFeb 10, 2021 9:35 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). With an estimated 20 million people in the United States suffering from SAD, it is one of the most prevalent mental health conditions in the…

Continue Reading

TuesdayFeb 09, 2021 12:03 pm

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Further Lab Results Validating Natural Biopesticide Control of Banana Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, as released additional lab results confirming its mustard-derived natural biopesticide ability to obtain 100% control of on the disease Fusarium wilt TR4. A banana disease often referred to as the Panama disease, Fusarium wilt TR4 is destroying the $25 billion global banana industry. These most-recent results were conducted by a third party and validate earlier test results that confirm the efficacy of MustGrow’s safe and effective natural, plant-based biopesticide. The test results confirm 100% control achieved at economic…

Continue Reading

TuesdayFeb 09, 2021 10:25 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Forms Clinical Advisory Board, Announces $25M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s novel gene therapy clinical development programs in cancer and diabetes. More specifically, CAB members will provide invaluable guidance and advise as Genprex advances its REQORSA(TM) (“REQORSA”) immunogene therapy program and its preclinical diabetes gene therapy program. Board members include the following: Michael Morse, MD, MHS,…

Continue Reading

TuesdayFeb 09, 2021 9:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Collaboration for Planned Phase 2 Clinical Trial of FW-1022

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced its entry into an agreement with PPD Inc. (NASDAQ: PPD ), a leading global contract research organization (“CRO”), for its planned Phase 2 clinical trial evaluating a proprietary formulation of micronized niclosamide as a treatment for COVID-19-associated GI infections. Under the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022. Licensed in January from FirstWave Bio Inc., the goal of AzurRx’s FW-1022 clinical program is…

Continue Reading

MondayFeb 08, 2021 11:46 am

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. “With our Helomics division’s deep experience in clinical profiling of patient tumor drug response, plus our unique PeDAL platform, we have all the components to perform in-house drug repositioning and even full drug discovery. We are…

Continue Reading